Cargando…
Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1
Treatment with anti-PD-L1 antibodies has shown efficacy in basal-like breast cancer. In this context, identification of pre-activated immune tumors is a main goal. Here we explore mutations in PD1 and PD-L1 high-expressing tumors to identify genomic correlates associated with outcome. To do so, RNA-...
Autores principales: | Cimas, Francisco J., Manzano, Arancha, Baliu-Piqué, Mariona, García-Gil, Elena, Pérez-Segura, Pedro, Nagy, Ádám, Pandiella, Atanasio, Győrffy, Balázs, Ocana, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464853/ https://www.ncbi.nlm.nih.gov/pubmed/32796628 http://dx.doi.org/10.3390/cancers12082243 |
Ejemplares similares
-
Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors
por: Alcaraz-Sanabria, Ana, et al.
Publicado: (2020) -
Breast Cancer Heterogeneity and Response to Novel Therapeutics
por: Baliu-Piqué, Mariona, et al.
Publicado: (2020) -
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
por: Pérez-Pena, Javier, et al.
Publicado: (2019) -
Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation
por: Noblejas-López, María del Mar, et al.
Publicado: (2021) -
Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer
por: Saiz-Ladera, Cristina, et al.
Publicado: (2021)